DYRK1A and type 1 diabetes mellitus: Thus, the important concept is that if and when effective immunomodulatory therapy emerges for T1D, or re-differentiation therapies emerge for T2D, human beta cell regenerative therapies, such as DYRK1A inhibitors, will be required to replenish beta cell mass in established T1D and T2D.